Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
Murao
S
S
Hirata
K
K
Ishida
T
T
Takahara
J
J
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001786:Blood Glucose / Q000187:drug effects*; D002839:Chromans / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D017258:Medroxyprogesterone Acetate / Q000009:adverse effects*; D008875:Middle Aged; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D000077288:Troglitazone
D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D017258:Medroxyprogesterone Acetate; D000077288:Troglitazone